country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

15 Years of Chromatin Factor Research: Lessons from HMGA Proteins and Future Horizons

Speaker

Indrabahadur Singh, PhD, MBA

• Emmy Noether Research Group Leader of Epigenetic Machineries and Cancer Research Group
• Founding Managing Director of PlexoA GmbH

In this Webinar, You Will Learn:

• The role of HMGA proteins in chromatin dynamics
• The functions of HMGA proteins in development and disease
• Emerging research avenues in chromatin factor studies

About this Webinar:

High Mobility Group A (HMGA) proteins are essential non-histone chromatin factors that significantly influence chromatin architecture and gene regulation. With their pivotal roles in cellular differentiation, proliferation, and tumor progression, HMGA proteins serve as key players in both normal cellular functions and disease mechanisms.

Recent studies have identified the embryonic isoform of GATA6 as a downstream target of HMGA2, currently under clinical trials for early lung cancer detection. Additionally, Let-7d, a negative regulator of HMGAs, plays a crucial role in nuclear gene suppression and chromatin organization through the formation of the MiCEE complex. Disruption of this complex has been linked to enhanced fibrosis progression, while its reassembly via EP300 inhibition offers a promising therapeutic strategy to halt fibrosis progression. Furthermore, HMGA proteins facilitate the deposition and phosphorylation of H2AX, a key modification essential for transcriptional activation and chromatin remodeling.

This webinar will delve into these groundbreaking discoveries, highlighting over 15 years of HMGA research. It will explore their clinical implications, and unveil innovative approaches to tackle unanswered questions in chromatin biology and disease management. Join us for an engaging discussion on the future of HMGA proteins as therapeutic targets for cancer, fibrosis-related disorders, and beyond.

A recording of the webinar will be shared to all registrants.
Participants can request a webinar certificate by contacting [email protected]

About Dr. Singh

Dr. Indrabahadur Singh is the head of the Emmy Noether Research Group at the German Cancer Research Center (DKFZ) in Heidelberg. With over a decade of experience in biomedical research, his work has significantly advanced the understanding of epigenetic mechanisms in development and disease. Dr. Singh has extensive publication record in peer-reviewed journals and collaborates with global research institutions to drive therapeutic advancements. He is committed to bridging the gap between preclinical findings and clinical applications. In addition, he is a founding managing director of PlexoA GmbH, dedicated to supporting biotech and biopharma startups in developing cancer treatments.

Learn More Dr. Singh and his research:
dkfz.de/en/chronische-entzuendung-und-krebs/team-indra/index.html

Recent Publications:

[1]. Preliminary results from the EMoLung clinical study showing early lung cancer detection by the LC score. Discov Oncol. 2023 Oct 3;14(1):181. [Content Brief]

[2]. EP300 as a Molecular Integrator of Fibrotic Transcriptional Programs. Int J Ml Sci. 2023 Aug 1;24(15):12302. [Content Brief]

[3]. Editorial: Metabolism and Epigenetics. Front Genet. 2022 Mar 10;13:877538. [Content Brief]

[4]. Positioning of nucleosomes containing Ƴ-H2AX precedes active DNA demethylation and transcription initiation. Nat Commun. 2021 Feb 16;12(1):1072. [Content Brief]

[5]. Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis. Nat Commun. 2019 May 20;10(1):2229. [Content Brief]

[6]. MiCEE is a ncRNA-protein complex that mediates epigenetic silencing and nucleolar organization. Nat Genet. 2018 Jul;50(7):990-1001. [Content Brief]

[7]. Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate. EMBO Mol Med. 2016 Dec 1;8(12):1380-1389. [Content Brief]

[8]. High mobility group protein-mediated transcription requires DNA damage marker Ƴ-H2AX. Cell Res. 2015 Jul;25(7):837-50. [Content Brief]

[9]. Hmga2 is required for canonical WNT signaling during lung development BMC Biol. 2014 Mar 24;12:21. [Content Brief]

[10]. HMGA proteins as modulators of chromatin structure during transcriptional activation. Front Cell Dev Biol. 2014 Mar 6;2:5. [Content Brief]